Among 2 analysts covering Zcl Composites Inc. (TSE:ZCL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Zcl Composites Inc. had 6 analyst reports since August 4, 2015 according to SRatingsIntel. The rating was upgraded by Raymond James to “Strong Buy” on Wednesday, November 4. Paradigm Research downgraded ZCL Composites Inc. (TSE:ZCL) on Friday, March 10 to “Hold” rating. See ZCL Composites Inc. (TSE:ZCL) latest ratings:
Enanta Pharmaceuticals, Inc. (ENTA) formed double top with $95.36 target or 9.00% above today’s $87.49 share price. Enanta Pharmaceuticals, Inc. (ENTA) has $1.68B valuation. The stock increased 1.40% or $1.21 during the last trading session, reaching $87.49. About 93,424 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 160.80% since April 21, 2017 and is uptrending. It has outperformed by 149.25% the S&P500.
The stock decreased 1.38% or $0.17 during the last trading session, reaching $12.11. About 6,429 shares traded. ZCL Composites Inc. (TSE:ZCL) has 0.00% since April 21, 2017 and is . It has underperformed by 11.55% the S&P500.
ZCL Composites Inc. designs, manufactures, and supplies fiberglass reinforced plastic underground storage tanks in Canada, the United States, and internationally. The company has market cap of $373.85 million. The firm operates through three divisions: Petroleum Products, Water Products, and Industrial Products. It has a 21.02 P/E ratio. The Petroleum Products segment provides underground fuel storage tanks for the downstream retail and commercial markets; tanks for midstream pipelines; tanks for the gas and oil exploration companies; Phoenix System that allows in-situ upgrades of steel or fiberglass tanks; and Parabeam, a three-dimensional glass fabric.
Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on May, 14. They expect $0.09 EPS, up 132.14% or $0.37 from last year’s $-0.28 per share. ENTA’s profit will be $1.72M for 243.03 P/E if the $0.09 EPS becomes a reality. After $0.78 actual EPS reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -88.46% negative EPS growth.
Since March 19, 2018, it had 0 insider purchases, and 2 sales for $1.14 million activity. On Monday, March 19 the insider MELLETT PAUL J sold $778,331. The insider Adda Nathalie sold $361,560.
Among 6 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 have Buy rating, 1 Sell and 4 Hold. Therefore 17% are positive. Enanta Pharmaceuticals Inc has $82.0 highest and $16 lowest target. $47.60’s average target is -45.59% below currents $87.49 stock price. Enanta Pharmaceuticals Inc had 24 analyst reports since August 7, 2015 according to SRatingsIntel. JP Morgan maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Tuesday, August 9 with “Overweight” rating. Robert W. Baird maintained Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Tuesday, August 8 with “Neutral” rating. JP Morgan downgraded the shares of ENTA in report on Thursday, February 8 to “Neutral” rating. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) earned “Mkt Outperform” rating by JMP Securities on Friday, October 23. The firm has “Hold” rating given on Monday, November 20 by Robert W. Baird. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has “Hold” rating given on Friday, October 20 by Robert W. Baird. On Friday, August 7 the stock rating was downgraded by Zacks to “Buy”. The rating was maintained by Robert W. Baird on Thursday, February 8 with “Hold”. J.P. Morgan downgraded the stock to “Hold” rating in Thursday, February 8 report. On Tuesday, January 2 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”.